Korro Bio

KRRO · NASDAQ

$9.44+$0.53 (+5.95%)TodayMarket closed · Oct 20, 7:41 PM ET

Prev close $8.91

KRRO analyst rating

BuyConsensus of 11 analysts over the last 12 months. 82% rate it a buy.

Strong buy0
Buy9
Hold2
Underperform0
Sell0

12-month price target · 13 analysts

Average $20.40 (+116.1% upside)

Low: $10.10
Now: $9.44
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

KRRO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 6, 2026	Maintains	Buy	$15.00	32%
HC Wainwright & Co.	Aug 20, 2026	Maintains	Buy	$15.00	32%
HC Wainwright & Co.	May 19, 2026	Maintains	Buy	$20.00 → $15.00	32%
Citigroup	May 18, 2026	Initiates	Buy	$21.00	42%
Cantor Fitzgerald	Mar 13, 2026	Maintains	Overweight	$21.00 → $22.00	39%
Raymond James	Mar 13, 2026	Upgrade	Market Perform → Outperform	$23.00	50%
Clear Street	Feb 19, 2026	Upgrade	Hold → Buy	$10.00 → $18.00	13%
William Blair	Feb 17, 2026	Upgrade	Market Perform → Outperform	—	55%
Chardan Capital	Jan 29, 2026	Upgrade	Neutral → Buy	$7.00 → $15.00	38%
HC Wainwright & Co.	Jan 29, 2026	Upgrade	Neutral → Buy	$20.00	32%

The case for and against

Updated Oct 17, 2026

Bull case

Korro Bio is attractive because KRRO-121 targets hyperammonemia with a clear, measurable clinical bar—blood ammonia below 200 μmol/L—making early proof-of-concept easier to assess and potentially broadening use across urea cycle disorders and hepatic encephalopathy regardless of mutation. The first cohort has been dosed in the Phase 1/2 ANCHOR study in Australia, with up to 50 healthy volunteers in Part 1 and up to 15 UCD patients in Part 2, while the AATD program added momentum through >70% SERPINA1 editing and repeat-dosing results above 90% editing. Financially, cash and marketable securities rose to $157.1M at 3/31/26, management guided runway into 2H28, and the net loss improved to $19.6M, supporting continued pipeline execution.

Bear case

Korro Bio is challenged by a valuation that depends on highly speculative assumptions, including a 13% discount rate, 1% terminal growth, and only $225M in estimated EV, while assigning just 20% approval odds to KRRO-121 in UCD and 10% to KRRO-111 in AATD. The outlook remains negative because the thesis is concentrated in a small pipeline, with the analysis explicitly excluding expansion into other programs and warning that KRRO-121 data and clinical progress could disappoint. Long-term dilution risk further weakens the fundamental case, as 20M fully-diluted shares are assumed and any financing needs could pressure per-share value.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.